ro glp-1 tracker Ro's Supply Helps Patients Locate In-Demand Drugs Amid Shortages The first ever FDA-approved GLP-1

However, the landmark SURMOUNT-5 trial (published in mid-2025), which compared the two medications head-to-head, clarified the clinical reality: Total Weight Loss: Tirzepatide drives significantly greater total weight loss (averaging over 20%) compared to semaglutide (averaging roughly 14%)

7 The effects of GLP-1RAs on the expressions of lysosomal proteins

We were able to schedule the appointment for the next day, and the video visit itself ran 1015 minutes through Google Meet, embedded inside the patient portal

The technology rapidly progressed with several types of co-agonists forging ahead in clinical trials including GIP/GLP-1 receptor dual agonists with one of the most notable being tirzepatide [8,9]